Posted by Peggy Kaufman
Last month more than 16,500 leaders of the biotechnology industry, hailing from 49 states and 65 countries, headed to Boston to attend the 2012 Bio International Convention. The JF&CS Fragile Beginnings program was highlighted at this global conference as a model of patient advocacy and partnerships with industry, thanks to our fruitful collaboration with MedImmune LLC. I was honored to be part of a panel discussion entitled “Fragile Beginnings: Biotech, Parents and Providers Partnering Together for Preemies,” moderated by Robert Coughlin, CEO of the Massachusetts Biotechnology Council. The topic of Fragile Beginnings certainly fit with the theme of BIO 2012: “Connect. Partner. Innovate.”
This post has been contributed by a third party. The opinions, facts and any media content are presented solely by the author, and JewishBoston assumes no responsibility for them. Want to add your voice to the conversation? Publish your own post here.